Which ETFs hold Neuren Pharmaceuticals Ltd (NEU)?
Australian biotech whose medicine for Rett syndrome is sold in the US by a partner.
21 Australian ETFs hold Neuren Pharmaceuticals Ltd, a Health Care company from Australia. SMLL has the biggest weighting at 2.21%. Across these funds, Australian ETF investors own about $68m of Neuren Pharmaceuticals Ltd.
The ETFs with the most Neuren Pharmaceuticals Ltd
All 21 ETFs that hold Neuren Pharmaceuticals Ltd, ranked by weight
Best-endeavours estimate. Built from each issuer's published holdings, which may be weeks or months old, may cover only part of a fund (some publish only their top 10) and are matched by company name. Figures may be incomplete or inaccurate. Check the issuer's website and PDS before relying on them. General information only.
Weights from each issuer's published holdings (September to November 2026). Some funds list only their largest holdings. General information only, not a recommendation to buy or sell Neuren Pharmaceuticals Ltd.
Common questions
Which ETF has the most Neuren Pharmaceuticals Ltd?
SMLL (Betashares Australian Small Companies Select ETF) has the highest weighting, with 2.21% of the fund in Neuren Pharmaceuticals Ltd.
What is the cheapest ETF that holds Neuren Pharmaceuticals Ltd?
Of the ETFs where Neuren Pharmaceuticals Ltd is at least 1% of the fund, SMLL has the lowest fee at 0.39% a year, with 2.21% in Neuren Pharmaceuticals Ltd.
How much Neuren Pharmaceuticals Ltd do I own with $10,000 in VAS?
About $9. VAS is the largest ETF that holds Neuren Pharmaceuticals Ltd, and Neuren Pharmaceuticals Ltd makes up 0.09% of it.
How many Australian ETFs hold Neuren Pharmaceuticals Ltd?
21 ETFs listed on the ASX or TMX Australia hold Neuren Pharmaceuticals Ltd, based on issuers' published holdings.